Live and let die: asymmetric dimethylarginine and septic shock

被引:0
作者
Rainer H Böger
机构
[1] University Hospital Hamburg-Eppendorf,Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology
来源
Critical Care | / 10卷
关键词
Nitric Oxide; Septic Shock; Sequential Organ Failure Assessment; Sequential Organ Failure Assessment Score; ADMA Level;
D O I
暂无
中图分类号
学科分类号
摘要
Nitric oxide (NO) is an important mediator of host defence and of vascular tone. In septic shock, upregulation of inducible NO synthase leads to the production of vast amounts of NO, which contribute to pathogen elimination but also to inappropriate vasodilation and to loss of vascular resistance. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthases shown to contribute to the regulation of vascular tone. ADMA was recently identified as a marker of organ dysfunction and mortality in intensive care patients and as a novel cardiovascular risk factor. In the present issue of Critical Care, a study by O'Dwyer and colleagues identifies ADMA as a potential regulator of NO production in septic shock. Being an inhibitor of NO production, ADMA may at least partly counteract pathological hypotension, but at the same time may impair the NO-dependent host defence. A mechanism is proposed by which the interplay between ADMA and inducible NO synthase activity is mediated. ADMA levels should be determined in future studies evaluating the regulation of NO in the intensive care setting.
引用
收藏
相关论文
共 50 条
  • [31] Septic shock
    Baxter, F
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1997, 44 (01): : 59 - 72
  • [32] Septic shock
    Klosterhalfen, B
    Bhardwaj, RS
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1998, 31 (01): : 25 - 32
  • [33] Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis
    Jacobi, J
    Sydow, K
    von Degenfeld, G
    Zhang, Y
    Dayoub, H
    Wang, BY
    Patterson, AJ
    Kimoto, M
    Blau, HM
    Cooke, JP
    CIRCULATION, 2005, 111 (11) : 1431 - 1438
  • [34] Turn Up the Hydroxyeicosatetraenoic on Septic Shock
    Thomas, Kirby
    Strong, Luke
    Fan, Fan
    Roman, Richard J.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (02) : 206 - 209
  • [35] Inodilators in septic shock: should these be used?
    Ospina-Tascon, Gustavo A.
    Calderon-Tapia, Luis E.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [36] Mechanisms of Vascular Hyporesponsiveness in Septic Shock
    Kimmoun, Antoine
    Ducrocq, Nicolas
    Levy, Bruno
    CURRENT VASCULAR PHARMACOLOGY, 2013, 11 (02) : 139 - 149
  • [37] Pathophysiology of cardiovascular dysfunction in septic shock
    Parker, MM
    NEW HORIZONS-THE SCIENCE AND PRACTICE OF ACUTE MEDICINE, 1998, 6 (02): : 130 - 138
  • [38] Mitochondrial dysfunction in human septic shock
    Brealey, D
    Nathan, A
    Davies, N
    Cooper, C
    Heales, S
    Land, J
    Singer, M
    BRITISH JOURNAL OF ANAESTHESIA, 1999, 82 (05) : 786P - 786P
  • [39] Septic circulatory shock and septic cardiomyopathy
    Werdan, K.
    Hettwer, S.
    Bubel, S.
    Oelke, A.
    Hoke, R. S.
    Wimmer, R.
    Ebelt, H.
    Mueller-Werdan, U.
    INTERNIST, 2009, 50 (07): : 799 - +
  • [40] MORE ON PATHOGENESIS AND TREATMENT OF SEPTIC SHOCK
    FUMAROLA, D
    PECE, S
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1992, 8 (05) : 761 - 762